iSpecimen (ISPC) risk factors, FY2025 10-K

Risks Related to Our Business

1. 01We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability28% rewritten
2. 02There is substantial doubt about our ability to continue as a going concern
3. 03A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis
4. 04We may likely require additional capital in the future and an inability to meet future capital needs could adversely impact our ability to operate
5. 05Our revenue trend is not predictive which can lead to difficulty in accurately forecasting future results
6. 06Ø Suppliers may not accurately estimate how long it will take them to fulfill specimen requests, making it more difficult to accurately forecast when we will recognize revenue on these specimen requests
7. 07Our growth strategy may not prove viable and we may not realize expected results
8. 08Ø We may lose to competitors, some of whom may have greater resources than we do. This competition may intensify due to the ongoing consolidation in the biospecimen industry, which may increase our costs to pursue opportunities
9. 09International operation expansion could expose us to additional risks which could harm our business, prospects, results of operation, and financial condition
10. 10We, or the third parties who provide services for us, may be adversely affected by external events for which our business continuity plans may not adequately prepare us
11. 11We rely upon our technology solution for the operation of our business and if our technology platform contains defects or fails to perform as expected, we may need to suspend its availability and divert development resources, and our business and reputation may be harmed
12. 12Sustainable future revenue growth is dependent upon the development of technology solutions that enable scale and address new markets
13. 13Our platform may become technologically obsolete or commoditized
14. 14Changes in demand for our products and services could affect profitability
15. 15If we fail to address these factors in a timely manner or at all, our financial results could be adversely affected
16. 16We incur credit risk with our customers, and we may provide them with products and services for which we do not get paid
17. 17Our customer mix increases the risk of customers not paying our invoices
18. 18We rely upon relatively few customers for a significant portion of revenue and do not have a recurring revenue business model. A loss of large customers could affect our ability to operate
19. 19Customers and customer prospects may be averse to using a self-service marketplace to procure specimens and may continue to require iSpecimen personnel in the procurement process, impacting our scalability and profitability
20. 20Our business may be materially and adversely impacted by the reduction, delay or cancellation of orders from our customers
21. 21We have entered into contracts with U.S. government agencies and contractors which subjects us to federal contract and audit risks25% rewritten
22. 22Ø change certain terms and conditions in our contracts
23. 23Sustainable future revenue growth is dependent on growth in the capabilities of our supply network which we may not be able to achieve
24. 24Sustainable future revenue growth is dependent upon gaining access to more healthcare data from our supply network and a failure to obtain this data may adversely affect our growth
25. 25The adoption cycle of our supply network tends to be very lengthy, which may adversely affect our ability to scale rapidly and increase revenues
26. 26Potential adverse effects from changes in the healthcare industry, including consolidations and regulatory changes, could affect access to subjects, samples, and data and affect our growth
27. 27Our supply chain may not provide adequate resources to quickly respond to requests for specimens and delays in the procurement process can affect our reputation, revenue, and profitability
28. 28We do not control the end-to-end quality of specimens and data collected in our supply chain and quality issues can affect our reputation, revenue, and profitability20% rewritten
29. 29Reliance on relatively few supply partners for significant supplies and services could affect our ability to operate and grow20% rewritten
30. 30Our supply partners’ inventories may become obsolete, which could have a material adverse effect upon our ability to generate revenue
31. 31Specimen collection from human subjects, including the possible occurrence of adverse events during or after tissue collection, could provide exposure to claims and litigation
32. 32We may experience delays or interruption in the shipments of our specimens due to factors outside of our control, and such disruption could lead to lost revenue and customer satisfaction issues
33. 33Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
34. 34Our senior management team has limited experience managing a public company
35. 35Our competitors may have greater resources than us and may outspend us to grow more quickly
36. 36We may lose business to competitors which have or develop their own biorepositories and/or collection centers that can meet customers’ needs
37. 37We may face pricing pressure from competitors who may lower prices to reduce biorepository inventories or because they have more favorable specimen acquisition costs
38. 38Our overall business results may suffer from an economic downturn
39. 39Our results of operations and financial condition may be adversely impacted from high inflation rates
40. 40Our timely fulfillment of customer orders may be adversely impacted due to constraints in the supply chain
41. 41We may have difficulty managing growth in our business, which could adversely affect our financial condition and results of operations
42. 42We have incurred losses from sales tax obligations owed to various jurisdictions by us because we did not collect taxes on taxable sales in prior years, and we may never be able to recover the prior sales taxes from the customers
43. 43Our ability to utilize net operating loss carryforwards may be limited, resulting in income taxes sooner than currently anticipated
44. 44We may acquire other businesses, products, or technologies that could disrupt our business, reduce our financial resources, or cause dilution to our stockholders
45. 45We may incur significant debt, and our governing documents contain no limit on the amount of debt we may incur
46. 46A failure to comply with restrictive covenants in the Purchase Agreement or our other financing arrangements would have a material adverse effect on us, and any future financings may require us to provide additional collateral or pay down debt

Risks Related to Intellectual Property

1. 47We use third-party technology licenses as part of our technology solution
2. 48We use open source licenses as part of our technology solution, which may subject us to claims from third parties claiming ownership and unauthorized use
3. 49We may become subject to third parties’ claims alleging infringement of their patents and proprietary rights, which could be costly, time consuming, and prevent the use of our technology solution
4. 50We do not have any patents protecting our intellectual property and if we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary and internally developed technology, our business could be adversely affected

Risks Related to Regulatory Environment

1. 51Failure to comply with federal and state data protection regulations could result in fines, penalties, and litigation, and have a material adverse effect upon our business
2. 52Failure to comply with international laws related to data protection, such as the General Data Protection Regulation (“GDPR”) could result in fines, penalties, and litigation, and have a material adverse effect upon the Company’s business
3. 53Failure to comply with federal and state laws around environmental, health and safety, biohazards and dangerous goods, and imports/exports could result in fines, penalties, and litigation, and have a material adverse effect upon our business
4. 54Failure to comply with other international laws around environmental, health and safety, biohazards and dangerous goods, imports/exports, and other regulations could result in fines, penalties, and litigation, and have a material adverse effect upon our business
5. 55Failure to comply with laws and regulations related to the protection of research subjects could result in fines, penalties, and litigation, and have a material adverse effect upon our business
6. 56Our failure to comply with other laws and regulations related to our business operations also have a material adverse effect upon our business
7. 57Ø State and local laws and regulations governing human subject research and clinical trials
8. 58Failure to comply with governmental export and import regulations could result in fines, penalties, and litigation, and have a material adverse effect upon the Company’s business
9. 59Specimens may have hazardous properties and may carry transmissible infectious agents. There are inherent risks in connection with the handling, storage, disposal, distribution, and/or use of the specimens

Risks Related to Our Securities

1. 60There can be no assurance that an active and liquid trading market for our common stock will continue or that we will be able to continue to comply with Nasdaq’s continued listing standards
2. 61We are not in compliance with Nasdaq’s minimum bid price requirement, and our common stock may be delisted if we fail to regain complianceNew
3. 62In the event that our common stock is delisted from Nasdaq, U.S. broker-dealers may be discouraged from effecting transactions in shares of our common stock because it may be considered a penny stock and thus be subject to the penny stock rules
4. 63The sale of substantial shares of our common stock may depress our stock price41% rewritten
5. 64Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders
6. 65Certain provisions of our certificate of incorporation, as amended, and our bylaws, as amended, may make it more difficult for a third party to affect a change-of-control
7. 66Our bylaws, as amended, designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees
8. 67Limitations on director and officer liability and indemnification of our officers and directors by us may discourage stockholders from bringing suit against an officer or director
9. 68We are responsible for the indemnification of our officers and directors
10. 69We do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock
11. 70We may need additional capital, and the sale of additional shares of common stock or other equity securities could result in additional dilution to our stockholders
12. 71Our quarterly revenue tends to fluctuate, making it harder to forecast and meet investor expectations
13. 72Our stock price may be volatile
14. 73Ø economic and other external factors
15. 74Our status as an “emerging growth company” under the JOBS Act may make it more difficult to raise capital when we need to do it or make our common stock less attractive to investors
16. 75We have limited insurance which may not cover claims by third parties against us or our officers and directors
17. 76The requirements of being a U.S. public company may strain our resources and divert management’s attention
18. 77Evaluation of internal control and remediation of potential problems will be costly and time consuming and could expose weaknesses in financial reporting
19. 78Public company compliance may make it more difficult to attract and retain officers and directors